Grifols SA (GRFS) Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - General
Grifols, S.A. NASDAQ:GRFS Healthcare · Drug Manufacturers - General
Mkt Cap $5.15B
Div Yield 1.40%
AH Close $7.56 +0.00% vs close
AH Close $7.56 +0.00% vs close
Mkt Cap $5.15B
Div Yield 1.40%
All Press Release SEC Filings News
News
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
zacks.com • 1mo ago News
Grifols says Canada plasma license suspension has no impact
reuters.com • 1mo ago News
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
seekingalpha.com • 1mo ago News
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
zacks.com • 1mo ago News
Oakmark International Small Cap Strategy Q2 2026 Portfolio Update
seekingalpha.com • 2mo ago Press Release
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
Grifols announced the completion of patient follow-up in its Phase 3 SPARTA trial evaluating Prolastin-C for emphysema due to alpha-1 antitrypsin deficiency.
The study is the largest randomized, double-blind, placebo-controlled trial in this indication to date, enrolling 345 participants across 37 sites in 16 countries.
Top line results are anticipated by the end of 2026, with the trial utilizing CT densitometry to measure the slowing of lung tissue loss.
• 2mo ago AI analysis › SEC Filing ⚠ 1
GRFS: 6-K · leadership change
Grifols, S.A. announced the resignation of Mr. Iñigo Sánchez-Asiaín Mardones from his positions as a member of the Board of Directors and as Chairperson of the Audit Committee, effective July 29, 2026, after nearly 12 years of service.
The Board unanimously appointed Ms. Joanna Susan Le Couilliard as a new independent director to fill the vacancy, bringing over 20 years of healthcare management experience. She was also appointed as the new Chairperson of the Audit Committee.
Additionally, the Board appointed Ms. Montserrat Muñoz Abellana as a new member of the Strategy Committee to replace the outgoing director.
SEC 6-K • 2mo ago AI analysis › News
Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago SEC Filing ⚠ 3
GRFS: 6-K · earnings release
Grifols reported first-half 2026 revenue of €3.57 billion, a 2.6% increase at constant currency, driven by a 5.4% rise in its Biopharma division. Net profit jumped 28.7% to €227 million, while the company successfully reversed its cash flow position to generate positive €91 million in free cash flow pre-M&A, a €103 million year-over-year improvement.
The company significantly strengthened its financial flexibility by refinancing all 2027 debt maturities, including a €3 billion equivalent Term Loan B and an upsized revolving credit facility. Consequently, Grifols now has no significant debt maturities until the fourth quarter of 2028 and maintains a robust liquidity position of €2.03 billion.
Strategic progress continues in Egypt with the plasma collection ramp-up and the upcoming inauguration of a new industrial complex. Additionally, Grifols is advancing its innovation pipeline, with top-line results from the Phase 3 SPARTA study for alpha-1 antitrypsin expected in late Q4 2026.
SEC 6-K • 2mo ago AI analysis › News
Grifols Q2 Earnings Call Highlights
marketbeat.com • 2mo ago Press Release
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols announced the dosing of the first patients in two Phase 3 trials, SIGMA and XPERT, designed to expand U.S. indications for its immunoglobulin franchise, GAMUNEX-C and XEMBIFY.
The SIGMA trial targets secondary immunodeficiency in patients with blood cancers, addressing a population of over 1 million in the U.S., while the XPERT trial aims to prove XEMBIFY's efficacy in CIDP.
These trials build on recent momentum for XEMBIFY, which grew nearly 60% year-over-year in 2025, and support Grifols' strategy to provide more treatment options for immune system disorders.
• 3mo ago AI analysis › News
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
seekingalpha.com • 3mo ago SEC Filing
GRFS: 6-K · leadership change
Grifols, S.A. acknowledged the resignation of Ms. Enriqueta Felip Font from the Board of Directors and the Sustainability, Communication and Reputation Committee, effective June 19, 2026, for professional reasons.
The Board of Directors unanimously appointed Ms. Ester Masllorens Llinàs as a new independent director via co-option to fill the vacancy, leveraging her over 20 years of international executive experience in the pharmaceutical sector.
Mr. Pascal Ravery was also appointed as a new member of the Sustainability, Communication and Reputation Committee, replacing Ms. Font.
SEC 6-K • 4mo ago AI analysis › SEC Filing ⚠ 1
GRFS: 6-K · other
Grifols, S.A. announced the results of its Ordinary General Shareholders' Meeting held on June 18, 2026. Shareholders approved a preferred dividend of EUR 0.01 per Class B share and an ordinary dividend of EUR 56,065,663, both payable on July 2, 2026.
The meeting also approved the re-election of Montserrat Muñoz Abellana and Susana González Rodríguez as independent directors and re-appointed Deloitte Auditores, S.L. as the statutory auditor for the fiscal years 2027-2029. Shareholders authorized the Board to increase share capital by up to 50% and acquire treasury shares up to 10% of the capital, while also approving a reduction of share capital via redemption of treasury shares up to 10% of the total capital.
An amendment to the directors' remuneration policy was approved, updating director fees and CEO performance metrics for the 2026 fiscal year. The resolution regarding the authorization to call Extraordinary General Shareholders' Meetings with 15 days' notice did not pass.
SEC 6-K • 4mo ago AI analysis › Press Release
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols has officially launched FESILTY (fibrinogen, human-chmt) in the United States, making its new fibrinogen concentrate available to patients with congenital fibrinogen deficiency.
The product, which received FDA approval in December 2025, is indicated for treating acute bleeding episodes in pediatric and adult patients with hypo- or afibrinogenemia, but not for dysfibrinogenemia.
FESILTY offers a purified, room-temperature-stable alternative to cryoprecipitate and fresh frozen plasma, allowing for rapid reconstitution in approximately three minutes and predictable dosing during critical bleeding events.
• 4mo ago AI analysis › SEC Filing
GRFS: 6-K · proxy statement
Grifols, S.A. has called an Ordinary General Shareholders' Meeting for June 17-18, 2026, to approve the annual accounts for the fiscal year ended December 31, 2025, and re-elect two board members.
The agenda includes routine governance matters such as the re-election of Deloitte as statutory auditor, amendments to the directors' remuneration policy, and a consultative vote on the Annual Remuneration Report.
Shareholders will also vote on authorizing the Board to increase share capital by up to 50% (with a 20% exclusion of pre-emptive rights) and to reduce capital by up to 10% via treasury share redemption, alongside renewing the authorization to list Class A shares on NASDAQ.
SEC 6-K • 5mo ago AI analysis › 
